

# Frank Spillmann

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7182389/frank-spillmann-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18  
papers

332  
citations

10  
h-index

18  
g-index

18  
ext. papers

440  
ext. citations

4.3  
avg, IF

3.11  
L-index

#	Paper	IF	Citations
18	Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis.. <i>ESC Heart Failure</i> , <b>2022</b> ,	3.7	1
17	Propensity score-based analysis of 30-day survival in cardiogenic shock patients supported with different microaxial left ventricular assist devices. <i>Journal of Cardiac Surgery</i> , <b>2021</b> , 36, 4141-4152	1.3	3
16	First in man evaluation of a novel circulatory support device: Early experience with the Impella 5.5 after CE mark approval in Germany. <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> , 40, 850-855	5.8	4
15	Case Report First-in-Man Method Description: Left Ventricular Unloading With iVAC2L During Venous-Arterial Extracorporeal Membrane Oxygenation: From Venous-Arterial Extracorporeal Membrane Oxygenation to ECMELLA to EC-iVAC. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 563448	5.4	2
14	Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 2838-2852	3.7	5
13	Prediction of survival of patients in cardiogenic shock treated by surgically implanted Impella 5+ short-term left ventricular assist device. <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2020</b> , 31, 475-482 <sup>1,8</sup>		10
12	Mode-of-action of the PROPELLA concept in fulminant myocarditis. <i>European Heart Journal</i> , <b>2019</b> , 40, 2164-2169	9.5	32
11	Mechanical Unloading by Fulminant Myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA Concepts. <i>Journal of Cardiovascular Translational Research</i> , <b>2019</b> , 12, 116-123	3.3	77
10	Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series. <i>European Heart Journal - Case Reports</i> , <b>2019</b> , 3,	0.9	15
9	Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial). <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 460-470	12.3	16
8	The CardioMEMS system in the clinical management of end-stage heart failure patients: three case reports. <i>BMC Cardiovascular Disorders</i> , <b>2018</b> , 18, 155	2.3	2
7	Multimodality imaging approach in the diagnosis of chronic myocarditis with preserved left ventricular ejection fraction (MCpEF): The role of 2D speckle-tracking echocardiography. <i>International Journal of Cardiology</i> , <b>2017</b> , 243, 374-378	3.2	27
6	Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions?. <i>BMC Cardiovascular Disorders</i> , <b>2017</b> , 17, 253	2.3	
5	NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	48
4	Human Endomyocardial Biopsy Specimen-Derived Stromal Cells Modulate Angiotensin II-Induced Cardiac Remodeling. <i>Stem Cells Translational Medicine</i> , <b>2016</b> , 5, 1707-1718	6.9	20
3	High-density lipoproteins reduce endothelial-to-mesenchymal transition. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2015</b> , 35, 1774-7	9.4	49
2	Cardiac effects of HDL and its components on diabetic cardiomyopathy. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , <b>2012</b> , 12, 132-47	2.2	10

- 1 High-density lipoprotein-raising strategies: update 2010. *Current Pharmaceutical Design*, **2010**, 16, 1517-30 11